HK Stock Market Move | Anker Innovations Technology (00668) saw an increase of nearly 7% in the afternoon trading session. Its subsidiary Anker SOLIX has signed a strategic cooperation agreement with Australia's OSW for 3GWh.
Anker Innovations (00668) rose nearly 7% in the late trading session, and as of this writing, it has increased by 6.09%, trading at HKD 116.7 with a transaction volume of HKD 32.8127 million.
Anker Innovations Technology (00668) rose nearly 7% in the late trading session, and as of the time of writing, it has increased by 6.09%, reaching HKD 116.7, with a trading volume of HKD 32.8127 million.
In recent news, Anker Innovations Technology's consumer energy brand Anker SOLIX has signed a strategic cooperation agreement for 3GWh of new energy storage with OSW, a well-known new energy distributor in Australia. The core products include new home storage solutions represented by Anker SOLIX XE, as well as next-generation photovoltaic, storage, and charging pile solutions aimed at the future.
Huaan pointed out that Anker Innovations Technology faced a decline in growth and stock price last year due to the recall of small chargers and the adjustment in the energy storage industry. We believe that with risks being cleared, the company is approaching a dual turning point in its fundamental valuationimprovements and upgrades in small chargers + large chargers entering a fast growth trajectory, leaving room for a rebound in valuation, along with the support of H-shares enhancing liquidity. The future dual increments of platformization and deepening will further elevate the long-term ceiling.
Related Articles

NEP INTERLONG (08329) issues a profit warning, expecting a mid-term net profit of approximately 7 million yuan.

FY FINANCIAL (08452) issued a profit warning, expecting a mid-term net loss of approximately 11 million to 12.5 million yuan.

Jiangsu Hengrui Pharmaceuticals (600276.SH): SHR-7590 injection has received approval for clinical drug trials.
NEP INTERLONG (08329) issues a profit warning, expecting a mid-term net profit of approximately 7 million yuan.

FY FINANCIAL (08452) issued a profit warning, expecting a mid-term net loss of approximately 11 million to 12.5 million yuan.

Jiangsu Hengrui Pharmaceuticals (600276.SH): SHR-7590 injection has received approval for clinical drug trials.

RECOMMEND





